944327-07-5

Upstream product

• 42900-98-1 3-ethyl-4-hydroxy-5-methylbenzaldehyde 
• 100-39-0 benzyl bromide 
• 107356-10-5 3-Chloro-4-hydroxy-5-methylbenzaldehyde 
• 1687-64-5 2-ethyl-6-methylphenol 
• 24549-06-2 6-ethyl-o-toluidine 

Downstream Products

• 1187029-86-2 {3-[5-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-[1,3,4]oxadiazol-2-yl]-5-methyl-benzyl}-ethyl-methyl-amine 
• 1187029-85-1 2-ethyl-4-(5-{3-[(ethyl-methyl-amino)-methyl]-5-methyl-phenyl}-[1,3,4]oxadiazol-2-yl)-6-methyl-phenol 
• 1160956-60-4 4-benzyloxy-3-ethyl-5-methyl-benzoic acid tert-butyl ester 
• 1160956-61-5 3-ethyl-4-hydroxy-5-methyl-benzoic acid tert-butyl ester 
• 1014691-18-9 4-benzyloxy-3-ethyl-5-methyl-benzoic acid N'-(4-isopropoxy-3-methyl-benzoyl)hydrazide 
• 1014691-19-0 2-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-5-(4-isopropoxy-3-methyl-phenyl)-[1,3,4]oxadiazole 
• 1062671-27-5 (S)-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,3,4]oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol 
• 1062671-33-3 (S)-N-(3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,3,4]oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062671-30-0 C₂₄H₃₃N₅O₃ 
• 1062671-19-5 4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenol 
• 1062671-23-1 {4-[5-(4-benzyloxy-3-ethyl-5-methylphenyl)-[1,3,4]oxadiazol-2-yl]-6-methylpyridin-2-yl}diethylamine 
• 1262414-35-6 (S)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)[1,3,4]oxadiazol-2-yl]-2-ethyl-6-methylphenoxy}propane-1,2-diol 
• 1262414-37-8 4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-2-ethyl-6-methylphenol 
• 1262414-36-7 4-[5-(4-benzyloxy-3-ethyl-5-methylphenyl)-[1,3,4]oxadiazol-2-yl]-2-cyclopentyl-6-methoxypyridine 

Relevant academic research and scientific papers

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

2-METHOXY-PYRIDIN-4-YL-DERIVATIVES

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

2-METHOXY-PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Thiophene derivatives as S1P1/EDGE1 receptor agonists

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Pyridin-4-yl derivatives as immunomodulating agents

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

NOVEL PYRIMIDINE DERIVATIVES

The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)

THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1

The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I).